Minimal benefit with adding antimuscarinics to alpha-blockers for benign prostatic hyperplasia

Clinical Question

Is the combination of antimuscarinics with alpha-blockers safe and effective for managing symptomatic benign prostatic hyperplasia?

Bottom line

This updated evidence review found minimal benefit with the addition of antimuscarinics to alpha-blockers for treating lower urinary tract symptoms in adults with BPH. Patients treated with antimuscarinics are at a higher risk of urinary retention, dry mouth, constipation, and dizziness. The antimuscarinics studied included oxybutynin, solifenacin, mirabegron, tolterodine, trospium, and vibegron, among others. 1a-

Study design: Meta-analysis (randomized controlled trials)

Funding: Self-funded or unfunded

Setting: Various (meta-analysis)

Reviewer

David C. Slawson, MD
Professor and Vice Chair of Family Medicine for Education and Scholarship
Atrium Health
Professor of Family Medicine, UNC Chapel Hill
Charlotte, NC


Discuss this POEM


Comments

DR ARUP KUMAR DHARA

Impact assessment

Very good

Anonymous

No

No